Klotho Neurosciences, Inc. (KLTO)

NASDAQ: KLTO · Real-Time Price · USD
1.550
-0.110 (-6.63%)
At close: Jun 17, 2025, 4:00 PM
1.500
-0.050 (-3.23%)
Pre-market: Jun 18, 2025, 7:56 AM EDT
-6.63%
Market Cap 50.37M
Revenue (ttm) n/a
Net Income (ttm) -7.71M
Shares Out 32.49M
EPS (ttm) -0.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,379,970
Open 1.600
Previous Close 1.660
Day's Range 1.400 - 1.610
52-Week Range 0.114 - 3.910
Beta 0.14
Analysts n/a
Price Target n/a
Earnings Date May 15, 2025

About KLTO

Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates comprise KLTO-101 for the treatment or prevention of Alzheimer’s disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig’s disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 3
Stock Exchange NASDAQ
Ticker Symbol KLTO
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

KLOTHO NEUROSCIENCES RAISES OVER $11 MILLION, RETIRES ALL DEBT, AND EXCEEDS NASDAQ STOCKHOLDERS' EQUITY REQUIREMENT

Highlights: Over $11 Million Raised: Proceeds were generated through the exercise of existing warrants. Chardan Capital Markets was the exclusive financial advisor in connection with public warrant ex...

2 days ago - PRNewsWire

Klotho Neurosciences: What's Behind The Nine-Fold Rise In KLTO Stock?

Klotho Neurosciences (KLTO) witnessed an astonishing 800% increase in stock value on June 9, 2025, after revealing positive results from pre-clinical studies. The company's investigations indicated th...

7 days ago - Forbes

KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO ("α-KLOTHO")

Recent clinical and pre-clinical studies and analysis indicates the potential to increase lifespan and reduce age-associated degeneration in multiple organ systems has be realized with a focus on the ...

9 days ago - PRNewsWire

Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis...

5 months ago - GlobeNewsWire

ANEW MEDICAL, INC. Secures Key Patent in Europe for Human Klotho Gene RNA Slice Variant and Protein

ANEW to explore therapeutics and specialty diagnostics utilizing the s-KL protein and will pursue other medical product development and commercial opportunities of interest Exclusive, worldwide intell...

1 year ago - GlobeNewsWire